Aktieanalys

Initiator Pharma Q3: A historical quarter - Redeye

Redeye Publicerad: 10 Nov 2023 09:45

Redeye provides a research update following the Q3 report published by Initiator Pharma earlier today. The company has managed to operate at a lower cash burn than we anticipated, boding well for the financial runway ahead. Furthermore, we are truly encouraged by the positive phase IIb topline results announced by the company during the quarter. We reiterate our recently raised fair value range with a base case valuation of SEK24 as we continue to have a positive outlook on the case.

Länk till analysen i sin helhet: https://www.redeye.se/research/958295/initiator-pharma-q3-a-historical-quarter?utm_source=finwire&utm_medium=RSS

Nyheter om Initiator Pharma

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!